A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of diseas

Publication Type:

Journal Article

Source:

Journal of translational medicine, Volume 6, p.6 (2008)

Keywords:

2008, Adolescent, Adult, APOPTOSIS, Cancer Vaccines, Center-Authored Paper, Clinical Research Division, Cytokine Analysis Core Facility, DENDRITIC CELLS, DISEASE PROGRESSION, Female, Flow Cytometry Core Facility, Genotype, Humans, Hypersensitivity, Delayed, Immune Monitoring Core Facility, Interleukin-10, Lymphocyte Activation, Male, MELANOMA, Middle Aged, Necrosis, Neoplasm Staging, Patient Selection, Phagocytosis, Polymorphism, Genetic, Predictive Value of Tests, Promoter Regions, Genetic, Shared Resources, Transplantation, Autologous

Abstract:

Sixteen melanoma patients (1 stage IIC, 8 stage III, and 7 stage IV) were treated in a Phase I study with a vaccine (DC/Apo-Nec) composed of autologous dendritic cells (DCs) loaded with a mixture of apoptotic/necrotic allogeneic melanoma cell lines (Apo-Nec), to evaluate toxicity and immune responses. Also, IL-10 1082 genotype was analyzed in an effort to predict disease progression.